ConMed
New Haven, Connecticut, 06513, United States
Location status: Recruiting
Location contact
CONTACT
NCT Number: NCT06948591
This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.
Interested in participating?
Request Info14 year–70 year
All sexes
Observational
New Haven, Connecticut, 06513, United States
Location status: Recruiting
CONTACT
This is a multi-center, single arm, open label registry investigating anterior cruciate ligament reconstruction (ACLR) procedures where the tissue graft is augmented with BioBrace®. Subjects meeting the inclusion/exclusion criteria will be enrolled retrospectively or prospectively. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 months, 1-, 2-, and 3-years post-operatively using various patient-reported outcome measures to assess pain, function, return to activity, and safety post-surgery.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.
An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.
Time frame: 3 years post-op
Improvement in function measured with International Knee Documentation Committee (IKDC) from baseline to 3 years post-surgery.
Time frame: Baseline, 6-months, 1-, 2-, and 3-years post-op
Evaluation of device-related adverse events
Time frame: Baseline, 6 months, 1-, 2-years post-op
Patient-reported functional and activity status as assessed by International Knee Documentation Committee (IKDC)
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Patient-reported functional and activity status as assessed by the following: Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Patient-reported functional and activity status as assessed by the following: Patient-Reported Outcomes Measurement Information System (PROMIS-10)
Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op
Patient-reported functional and activity status as assessed by: Tegner Activity Scale (TAS).
Time frame: 6 months, 1-, 2-, and 3-years post-op
Patient-reported functional and activity status as assessed by the following: Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)
Time frame: 6 months, 1-, 2-, and 3-years post-op
The percentage of subjects who required additional surgical procedures following discharge from the BioBrace ACLR index procedure will be reported.
Time frame: 6 months, 1-, 2-, and 3-years post-op
Re-tear rate of the surgically reconstructed ACL tissue graft augmented with BioBrace. The percentage of subjects who experienced a re-tear of the augmented ACL tissue graft will be reported.
Contact information is provided by the study sponsor or research team.
CONMED Corporation
Industry
Real World Evaluation of the Safety and Effectiveness of BioBrace® Augmentation in Anterior Cruciate Ligament (ACL) Reconstruction Procedures
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07046000
ACL Tears, Anterior Cruciate Ligament Injuries
Sugar Land, Texas, United States
View Trial DetailsNCT06781021
ACL Tears, Anterior Cruciate Ligament Injuries
Kingston, Jamaica
View Trial DetailsNCT03132987
ACL Tears, Anterior Cruciate Ligament Injuries
Omaha, Nebraska, United States
View Trial DetailsNCT07725016
ACL Injury, Anterior Cruciate Ligament Injuries
Lahore, Punjab Province, Pakistan
View Trial Details